Psychedelic-assisted psychotherapy: Where is the psychotherapy research
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Rationale Psychedelic-assisted psychotherapy (PAP) has emerged as a potential treatment for a variety of mental health conditions, including substance use disorders and depression. Current models of PAP emphasize the importance of psychotherapeutic support before, during, and after ingestion of a psychedelic to maximize safety and clinical benefit. Despite this ubiquitous assumption, there has been surprisingly little empirical investigation of the "psychotherapy" in PAP, leaving critical questions about the necessary and sufficient components of PAP unanswered. Objectives As clinical trials for psychedelic compounds continue the transition from safety- and feasibility-testing to evaluating efficacy, the role of the accompanying psychotherapy must be better understood to enhance scientific understanding of the mechanisms underlying therapeutic change, optimize clinical outcomes, and inform cost-effectiveness. Results The present paper first reviews the current status of psychotherapy in the PAP literature, starting with recent debates regarding "psychotherapy" versus "psychological support" and then overviewing published clinical trial psychotherapy models and putative models informed by theory. We then delineate lessons that PAP researchers can leverage from traditional psychotherapy research regarding standardizing treatments (e.g., publish treatment manuals, establish eligibility criteria for providers), identifying mechanisms of change (e.g., measure established mechanism…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Psychedelic-assisted psychotherapy (PAP), a therapeutic approach augmenting talking therapy with psychedelic substances, has been recently classified as a potential breakthrough treatment for psychiatric illness (19).”
From Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol (2025) · cites this paper as [19]
Citations
Cites
On making causal claims: A review and recommendations
Antonakis, J., Bendahan, S., Jacquart, P., & Lalive, R. (2010) · The Leadership Quarterly · doi:10.1016/j.leaqua.2010.10.010 · Cited by 2,441 · cited 1×
“The primary advantage of CLPMs compared to traditional cross-sectional correlational analyses is accounting for temporality, a primary criterion for causal inference (Antonakis et al. 2010).”
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 2×
“The psychedelic peak therapy model includes a semi-structured approach to adjunctive psychotherapy, historically described as a “non-directive supportive” framework, in which therapists minimize verbal interactions with participants during the dosing experience (Griffiths et al. 2016).”
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698 · cited 2×
“Nonetheless, the psyche-delic peak therapy model has been ubiquitously applied to modern PAP research—across various psychedelic drugs, research groups, and clinical diagnoses (Davis et al. 2021b; Johnson et al. 2014; Ross et al. 2016).”
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391
Clinical psychology: Science and practice.
Kazdin, A. E. (1994) · Clinical Psychology: Science and Practice · doi:10.1111/j.1468-2850.1994.tb00001.x · Cited by 1,357
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301 · cited 2×
“Nonetheless, the psyche-delic peak therapy model has been ubiquitously applied to modern PAP research—across various psychedelic drugs, research groups, and clinical diagnoses (Davis et al. 2021b; Johnson et al. 2014; Ross et al. 2016).”
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203 · cited 1×
“Subsequent integration sessions assist participants in making meaning of their experiences and exploring ways of potentially generalizing insights from the dosing session to improve their daily lives (Johnson et al. 2008).”
REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180 · cited 1×
“…risks that are thought to be mitigated with therapeutic support (Schlag et al. 2022); and (2) Efficacy : psychedelics appear to transiently relax prior beliefs (Carhart-Harris and Friston 2019), increase suggestibility (Carhart-Harris et al. 2015), and promote neuroplasticity (Nardou et al. 2023).”
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206443 · Cited by 1,167 · cited 1×
“Yet, the same researchers expressing skepticism of the necessity of psychotherapy in PAP recently published a phase 2 clinical trial (Goodwin et al. 2022) that included (a) trained “therapists” present at each stage of the study intervention, (b) an unpub-lished “therapist manual” guiding therapist…”
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 2×
“…have incorporated other modalities of psychotherapy in the preparation and integration phases, including CBT (Johnson et al. 2014), Motivational Enhancement Therapy (Bogenschutz et al. 2015, 2022), and an eclectic treatment drawing from existential, psychodynamic, and CBT models (Ross et al. 2016).”
Some implicit common factors in diverse methods of psychotherapy.
Rosenzweig, S. (1936) · American Journal of Orthopsychiatry · doi:10.1111/j.1939-0025.1936.tb05248.x · Cited by 1,042 · cited 1×
“Indeed, this has been a sim-mering issue for the field of psychotherapy for almost a century (Rosenzweig 1936).”
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 5×
“Yet, the same researchers expressing skepticism of the necessity of psychotherapy in PAP recently published a phase 2 clinical trial (Goodwin et al. 2022) that included (a) trained “therapists” present at each stage of the study intervention, (b) an unpub-lished “therapist manual” guiding therapist interactions with p…”
InfluentialPalhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852 · cited 1×
“This may be a particularly relevant hurdle for PAP, given that the treatment involves a limited number of sessions relative to traditional psychotherapy and can be characterized by periods of rapid, non-linear change in some cases (Palhano-Fontes et al. 2019).”
The Role of Common Factors in Psychotherapy Outcomes
Cuijpers, P., Reijnders, M., & Huibers, M. J. H. (2019) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050718-095424 · Cited by 748 · cited 1×
“…techniques (e.g., therapeutic alliance, positive expectations, hope, reassurance) often makes it difficult to identify outcome differences among approaches when directly compared in a clinical trial (Cuijpers et al. 2019), a phenomenon referred to as “The Dodo Bird Verdict” (Luborsky et al. 2002).”
Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2096 · Cited by 711 · cited 2×
“…have incorporated other modalities of psychotherapy in the preparation and integration phases, including CBT (Johnson et al. 2014), Motivational Enhancement Therapy (Bogenschutz et al. 2015, 2022), and an eclectic treatment drawing from existential, psychodynamic, and CBT models (Ross et al. 2016).”
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117731279 · Cited by 520
Hartogsohn, I. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116677852 · Cited by 483 · cited 1×
“…to context (i.e., extra-pharmaco-logical variables) necessitates a nuanced understanding of the optimal dose and modality of psychotherapy to pair with clinical administration of a psychedelic compound to maximize participant safety and clinical effectiveness (Devenot et al. 2022; Hartogsohn 2016).”
Therapeutic alliance as a mediator of change: A systematic review and evaluation of research
Baier, A. L., Kline, A. C., & Feeny, N. C. (2020) · Clinical Psychology Review · doi:10.1016/j.cpr.2020.101921 · Cited by 441 · cited 2×
“Defining the eligibility criteria for care providers (e.g., training, licensure) may also promote consistency of intervention delivery and mitigate risks for boundary violations (Baier et al. 2020).”
Psychedelics reopen the social reward learning critical period
Nardou, R., Sawyer, E., Song, Y. J., Wilkinson, M., Padovan-Hernandez, Y., de Deus, J. L., Wright, N., Lama, C., Faltin, S., Goff, L. A., et al. (2023) · Nature · doi:10.1038/s41586-023-06204-3 · Cited by 358 · cited 1×
“…risks that are thought to be mitigated with therapeutic support (Schlag et al. 2022); and (2) Efficacy : psychedelics appear to transiently relax prior beliefs (Carhart-Harris and Friston 2019), increase suggestibility (Carhart-Harris et al. 2015), and promote neuroplasticity (Nardou et al. 2023).”
Doss, M. K., Považan, M., Rosenberg, M. D., Sepeda, N. D., Davis, A. K., Finan, P. H., Smith, G. S., Pekar, J. J., Barker, P. B., Griffiths, R. R., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01706-y · Cited by 356 · cited 1×
“…change have been identified in PAP, such as awe (Hendricks 2018), mystical-type experiences (Griffiths et al. 2016), acceptance (Wolff et al. 2020), decreased rumination (Barba et al. 2022), cognitive flexibility (Doss et al. 2021), and therapeutic alliance (Levin et al. 2024; Murphy et al. 2021).”
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069100 · Cited by 325 · cited 1×
“…approach: (1) Safety : High doses of psychedelics can confer acute psychological risks that are thought to be mitigated with therapeutic support (Schlag et al. 2022); and (2) Efficacy : psychedelics appear to transiently relax prior beliefs (Carhart-Harris and Friston 2019), increase…”
Self-citationLSD enhances suggestibility in healthy volunteers
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3714-z · Cited by 320
The use of the psychological flexibility model to support psychedelic assisted therapy
Watts, R., & Luoma, J. B. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.12.004 · Cited by 269 · cited 1×
“…(Moreton et al. 2020), mindfulness (Felsch and Kuypers 2022), psychoanalysis (Guss 2022), group psycho-therapy (Trope et al. 2019), virtual reality therapy (Aday et al. 2020), and even novel modalities specifically designed for PAP (Brennan and Belser 2022; Wolfson 2022; Watts and Luoma 2020).”
Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression
Murphy, R., Kettner, H., Zeifman, R., Giribaldi, B., Kartner, L., Martell, J., Read, T., Murphy-Beiner, A., Baker-Jones, M., Nutt, D., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.788155 · Cited by 250
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Schenberg, E. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00733 · Cited by 240
Aday, J. S., Heifets, B. D., Pratscher, S. D., Bradley, E., Rosen, R., & Woolley, J. D. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06123-7 · Cited by 237
Self-citationMethodological Recommendations for Trials of Psychological Interventions
Guidi, J., Brakemeier, E.-L., Bockting, C. L. H., Cosci, F., Cuijpers, P., Jarrett, R. B., Linden, M., Marks, I., Peretti, C. S., Rafanelli, C., et al. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000490574 · Cited by 205 · cited 1×
“In 2018, an international group of psycho-therapy researchers published recommendations to improve rigor in psychotherapy trials (Guidi et al. 2018).”
Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance
Wolff, M., Evens, R., Mertens, L. J., Koslowski, M., Betzler, F., Gründer, G., & Jungaberle, H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00005 · Cited by 194 · cited 1×
“…mechanisms of change have been identified in PAP, such as awe (Hendricks 2018), mystical-type experiences (Griffiths et al. 2016), acceptance (Wolff et al. 2020), decreased rumination (Barba et al. 2022), cognitive flexibility (Doss et al. 2021), and therapeutic alliance (Levin et al. 2024;…”
Must Psilocybin Always “Assist Psychotherapy”?
Goodwin, G. M., Malievskaia, E., Fonzo, G. A., & Nemeroff, C. B. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20221043 · Cited by 189
Schnurr, P. P., Chard, K. M., Ruzek, J. I., Chow, B. K., Resick, P. A., Foa, E. B., Marx, B. P., Friedman, M. J., Bovin, M. J., Caudle, K. L., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.36921 · Cited by 185 · cited 1×
“These analyses underscore the importance of head-to-head interventions, as treatments that share similar effectiveness may benefit from treatment tailoring to minimize patient dropout (see: Schnurr et al. 2022).”
The Great Psychotherapy Debate
Wampold, B. E., & Wampold, B. E. (2013) · Routledge eBooks · doi:10.4324/9780203893340 · Cited by 183
Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy
Hendricks, P. S. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1474185 · Cited by 179 · cited 1×
“Similarly, a range of putative psychological mechanisms of change have been identified in PAP, such as awe (Hendricks 2018), mystical-type experiences (Griffiths et al. 2016), acceptance (Wolff et al. 2020), decreased rumination (Barba et al. 2022), cognitive flexibility (Doss et al. 2021), and…”
Psychedelic Drug Legislative Reform and Legalization in the US
Siegel, J. S., Daily, J. E., Perry, D. A., & Nicol, G. E. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.4101 · Cited by 179 · cited 1×
“Relatedly, the importance of establishing clear guidelines and standards for appropriate licensure and training of psychedelic therapists is of the utmost importance (Feduccia et al. 2023; Siegel et al. 2023).”
Sloshower, J., Guss, J., Krause, R., Wallace, R. M., Williams, M. T., Reed, S., & Skinta, M. D. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.002 · Cited by 171 · cited 2×
“The list of approaches that have been proposed to be synergistic with PAP cascades into a myriad of psychotherapies, including Acceptance and Commitment Therapy (Sloshower et al. 2020), Internal Family Systems Therapy (IFST; Morgan 2020), Eye Movement Desensitization and Reprocessing Therapy (EMDR; Rose and Raine-Smit…”
Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions
Cavarra, M., Falzone, A., Ramaekers, J. G., Kuypers, K. P. C., & Mento, C. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.887255 · Cited by 171 · cited 1×
“…regarding best psychotherapeutic practices for PAP vary widely beyond the standard psyche-delic peak therapy framework that includes “non-directive support”, and there has been very limited empirical investigation to date of these diverse approaches in the context of PAP (Cavarra et al. 2022).”
Davis, A. K., Barrett, F. S., So, S., Gukasyan, N., Swift, T. C., & Griffiths, R. R. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120967878 · Cited by 169 · cited 1×
“Regarding insight, evidence is emerging that experiences of insight facilitated with psychedelics may predict persisting clinical benefits (Davis et al. 2021a; Peill et al. 2022), although further research is needed.”
McNamee, S., Devenot, N., & Buisson, M. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.0099 · Cited by 168 · cited 1×
“This ambiguity regarding what is PAP, and the guidelines for training of psychedelic therapists, have contributed to uncertainty surrounding best practices for the field and raised the risk of ethical and boundary violations (McNamee et al. 2023).”
Gukasyan, N., & Nayak, S. M. (2022) · Transcultural Psychiatry · doi:10.1177/1363461520983684 · Cited by 150
Peill, J. M., Trinci, K. E., Kettner, H., Mertens, L. J., Roseman, L., Timmermann, C., Rosas, F. E., Lyons, T., & Carhart-Harris, R. L. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211066709 · Cited by 141 · cited 1×
“Regarding insight, evidence is emerging that experiences of insight facilitated with psychedelics may predict persisting clinical benefits (Davis et al. 2021a; Peill et al. 2022), although further research is needed.”
Psychedelic-Assisted Group Therapy: A Systematic Review
Trope, A., Anderson, B. T., Hooker, A. R., Glick, G., Stauffer, C., & Woolley, J. D. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1593559 · Cited by 113 · cited 1×
“…2023), existential psychology (Moreton et al. 2020), mindfulness (Felsch and Kuypers 2022), psychoanalysis (Guss 2022), group psycho-therapy (Trope et al. 2019), virtual reality therapy (Aday et al. 2020), and even novel modalities specifically designed for PAP (Brennan and Belser 2022;…”
Self-citationZeifman, R. J., Wagner, A. C., Watts, R., Kettner, H., Mertens, L. J., & Carhart-Harris, R. L. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00782 · Cited by 106 · cited 1×
“…there may be additional mechanisms of change derived from traditional psychotherapy (e.g., mindfulness, experiential avoidance; Payne et al. 2021; Zeifman et al. 2020) that are applicable to PAP, and it should also be highlighted that PAP may involve unique mechanisms that traditional…”
Set and setting: a randomized study of different musical genres in supporting psychedelic therapy
Strickland, J. C., Garcia-Romeu, A., & Johnson, M. W. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00187 · Cited by 97
Moreton, S. G., Szalla, L., Menzies, R. E., & Arena, A. F. A. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05391-0 · Cited by 93 · cited 1×
“…Therapy (IFST; Morgan 2020), Eye Movement Desensitization and Reprocessing Therapy (EMDR; Rose and Raine-Smith 2023), existential psychology (Moreton et al. 2020), mindfulness (Felsch and Kuypers 2022), psychoanalysis (Guss 2022), group psycho-therapy (Trope et al. 2019), virtual reality…”
Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy
Horton, D. M., Morrison, B., & Schmidt, J. (2021) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.20200055 · Cited by 93 · cited 2×
“Contemporary clinical trials of PAP often include the same general sequence for the intervention, comprising three stages: preparation, dosing, and integration (Horton et al. 2021).”
Self-citationYunitri, N., Chu, H., Kang, X. L., Wiratama, B. S., Lee, T., Chang, L., Liu, D., Kustanti, C. Y., Chiang, K., Chen, R., et al. (2023) · Psychological Medicine · doi:10.1017/s0033291722003737 · Cited by 93
Brennan, W., & Belser, A. B. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.866018 · Cited by 90 · cited 1×
“…(Moreton et al. 2020), mindfulness (Felsch and Kuypers 2022), psychoanalysis (Guss 2022), group psycho-therapy (Trope et al. 2019), virtual reality therapy (Aday et al. 2020), and even novel modalities specifically designed for PAP (Brennan and Belser 2022; Wolfson 2022; Watts and Luoma 2020).”
Golden, T. L., Magsamen, S., Sandu, C. C., Lin, S., Roebuck, G. M., Shi, K. M., & Barrett, F. S. (2022) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2021_298 · Cited by 85
Levin, A. W., Lancelotta, R., Sepeda, N. D., Gukasyan, N., Nayak, S., Wagener, T. L., Barrett, F. S., Griffiths, R. R., & Davis, A. K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300501 · Cited by 82 · cited 2×
“Similarly, therapeutic alliance between therapists and participants in PAP appears predictive of greater emotional breakthrough, mystical-type experiences, and decreases in depression (Levin et al., 2024; Murphy et al. 2021), but has most often not been measured.”
Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry
Barber, G., & Dike, C. C. (2023) · Psychiatric Services · doi:10.1176/appi.ps.20220525 · Cited by 82 · cited 1×
“Such considerations are paramount for PAP, as participants are given suggestibility-enhancing substances that may increase their vulnerability to therapist coercion and malpractice (Carhart-Harris et al. 2015; Barber and Dike 2023; Villiger and Trachsel 2023).”
Lower-dose psycholytic therapy – A neglected approach
Passie, T., Guss, J., & Krähenmann, R. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1020505 · Cited by 81 · cited 1×
“…could likely be better mechanistically understood and clinically optimized by leveraging the techniques developed in the context of traditional psychotherapy, and it may be the case that certain psychotherapeutic approaches may be more suitable for specific doses or conditions (Passie et al. 2022).”
Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice
Payne, J. E., Chambers, R., & Liknaitzky, P. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00034 · Cited by 78 · cited 1×
“…principles, there may be additional mechanisms of change derived from traditional psychotherapy (e.g., mindfulness, experiential avoidance; Payne et al. 2021; Zeifman et al. 2020) that are applicable to PAP, and it should also be highlighted that PAP may involve unique mechanisms that…”
Falkenström, F., Solomonov, N., & Rubel, J. (2020) · Counselling and Psychotherapy Research · doi:10.1002/capr.12293 · Cited by 71
Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry
Aday, J. S., Barnett, B. S., Grossman, D., Murnane, K. S., Nichols, C. D., & Hendricks, P. S. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0013 · Cited by 68 · cited 1×
“Due to the difficulty of patenting and monetizing psychotherapy approaches, companies in the psychedelic industry are incentivized to focus on drug discovery and development (Aday et al. 2023b).”
Self-citationA Psychoanalytic Perspective on Psychedelic Experience
Guss, J. R. (2022) · Psychoanalytic Dialogues · doi:10.1080/10481885.2022.2106140 · Cited by 66 · cited 1×
“…have incorporated other modalities of psychotherapy in the preparation and integration phases, including CBT (Johnson et al. 2014), Motivational Enhancement Therapy (Bogenschutz et al. 2015, 2022), and an eclectic treatment drawing from existential, psychodynamic, and CBT models (Ross et al. 2016).”
Psychedelic Identity Shift: A Critical Approach to Set And Setting
Devenot, N., Seale‐Feldman, A., Smith, E., Noorani, T. N., Garcia‐Romeu, A., & Johnson, M. W. (2022) · Kennedy Institute of Ethics journal · doi:10.1353/ken.2022.0022 · Cited by 66 · cited 1×
“…to context (i.e., extra-pharmaco-logical variables) necessitates a nuanced understanding of the optimal dose and modality of psychotherapy to pair with clinical administration of a psychedelic compound to maximize participant safety and clinical effectiveness (Devenot et al. 2022; Hartogsohn 2016).”
Barnett, B. S., Parker, S. E., & Weleff, J. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103473 · Cited by 62 · cited 1×
“A final critical issue to underscore, however, is the paucity of federal funding for psychedelic studies, which has forced researchers to primarily rely on philanthropic and industry support for trials (Barnett et al. 2022).”
Effects of psilocybin versus escitalopram on rumination and thought suppression in depression
Barba, T., Buehler, S., Kettner, H., Radu, C., Cunha, B. G., Nutt, D. J., Erritzoe, D., Roseman, L., & Carhart-Harris, R. (2022) · BJPsych Open · doi:10.1192/bjo.2022.565 · Cited by 57 · cited 1×
“…change have been identified in PAP, such as awe (Hendricks 2018), mystical-type experiences (Griffiths et al. 2016), acceptance (Wolff et al. 2020), decreased rumination (Barba et al. 2022), cognitive flexibility (Doss et al. 2021), and therapeutic alliance (Levin et al. 2024; Murphy et al. 2021).”
Aday, J. S., Skiles, Z., Eaton, N., Fredenburg, L., Pleet, M. M., Mantia, J., Bradley, E., Fernandes‐Osterhold, G., & Woolley, J. D. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2022.0004 · Cited by 56 · cited 4×
“…experiences, such as “guide” (Leary 1966), “sitter” (Thal et al. 2022a) “monitor” (Ching et al. 2023), “facilitator” (Golden et al. 2022), and “psychedelic therapist” (Aday et al. 2023a), among others, underscores the lack of consensus in the field concerning the psychotherapeutic component.”
InfluentialSelf-citationBrennan, B., Kelman, A. R., & Belser, A. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0007 · Cited by 52 · cited 1×
“Descriptions of the psychotherapeutic components of PAP have typically been minimized (Brennan et al. 2023); speculatively, this may be because many of the researchers in this area are not psychotherapists themselves and that manualizing interpersonal interactions can be intrinsically challenging.”
Dismantling Studies of Psychotherapy
Papa, A., & Follette, W. C. (2015) · The Encyclopedia of Clinical Psychology · doi:10.1002/9781118625392.wbecp523 · Cited by 48 · cited 1×
“…removed portion of the treatment is an important “ingredient” in the overall treatment package, subsequent group comparisons should demonstrate reductions in clinically significant change in the dismantled group as compared to the group that received the complete treatment (Papa and Follette 2015).”
Psychedelics and virtual reality: parallels and applications
Aday, J. S., Davoli, C. C., & Bloesch, E. K. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320948356 · Cited by 47 · cited 1×
“…(Moreton et al. 2020), mindfulness (Felsch and Kuypers 2022), psychoanalysis (Guss 2022), group psycho-therapy (Trope et al. 2019), virtual reality therapy (Aday et al. 2020), and even novel modalities specifically designed for PAP (Brennan and Belser 2022; Wolfson 2022; Watts and Luoma 2020).”
Self-citationEmerging Challenges for Psychedelic Therapy
Aday, J. S., Carhart-Harris, R. L., & Woolley, J. D. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.0549 · Cited by 47 · cited 4×
“…experiences, such as “guide” (Leary 1966), “sitter” (Thal et al. 2022a) “monitor” (Ching et al. 2023), “facilitator” (Golden et al. 2022), and “psychedelic therapist” (Aday et al. 2023a), among others, underscores the lack of consensus in the field concerning the psychotherapeutic component.”
InfluentialSelf-citationVilliger, D., & Trachsel, M. (2023) · Journal of Medical Ethics · doi:10.1136/jme-2022-108816 · Cited by 45 · cited 1×
“Such considerations are paramount for PAP, as participants are given suggestibility-enhancing substances that may increase their vulnerability to therapist coercion and malpractice (Carhart-Harris et al. 2015; Barber and Dike 2023; Villiger and Trachsel 2023).”
The need for establishing best practices and gold standards in psychedelic medicine
Feduccia, A., Agin-Liebes, G., Price, C. M., Grinsell, N., Paradise, S., & Rabin, D. M. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.03.083 · Cited by 43 · cited 2×
“Although these sources of knowledge have been incredibly valuable for the field, systematic study of the psychotherapy in PAP has been lacking (Feduccia et al. 2023).”
Wolff, M., Evens, R., Mertens, L. J., Schmidt, C., Beck, J. L., Rutrecht, H. M., Cherniak, A. D., Gründer, G., & Jungaberle, H. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241249698 · Cited by 42 · cited 1×
“In summary, many cognitive-emotional and interpersonal processes involved in PAP are also core constructs targeted in psychotherapy interventions (Wolff et al. 2024).”
Thal, S. B., Baker, P., Marinis, J., Wieberneit, M., Sharbanee, J. M., Bruno, R., Skeffington, P., & Bright, S. J. (2023) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.2945 · Cited by 38 · cited 1×
“…contains distinct approaches to providing adjunctive psychotherapy, with more traditional forms of structured psychotherapy present during the preparation and integration stages of treatment, and a semi-structured, “non-directive” approach during dosing sessions (Thal et al. 2022b, 2023, 2024).”
O’Donnell, K. C., Anderson, B. T., Barrett, F. S., Bogenschutz, M. P., Grob, C. S., Hendricks, P. S., Kelmendi, B., Nayak, S. M., Nicholas, C. R. N., Paleos, C. A., et al. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230661 · Cited by 38 · cited 1×
“…from researchers across the globe expressing concern that minimizing the psychotherapeutic component of treatment could compromise the safety and efficacy of PAP (Alpert et al. 2024; Bogenschutz 2024; Deckel et al. 2024; Earleywine et al. 2024; O’Donnell et al. 2024; Schenberg et al. 2024).”
NIMH’s Straight and Neural Path: The Road to Killing Clinical Psychiatric Research
Markowitz, J. C., & Friedman, R. A. (2020) · Psychiatric Services · doi:10.1176/appi.ps.202000057 · Cited by 34 · cited 1×
“Moreover, although the National Institute of Health (NIH) has recently released requests for applications for psychedelic research investigations, the NIH’s de-emphasis on psychotherapy research more generally (Karter 2015; Markowitz and Friedman 2020)”
Williams, C., Skinner, E. H., James, A. M., Cook, J. L., McPhail, S., & Haines, T. P. (2016) · Trials · doi:10.1186/s13063-016-1535-6 · Cited by 33 · cited 1×
“Similarly, comparative efficacy and non-inferiority trials compare two active forms of treatment to assess treat-ment superiority after a treatment has demonstrated efficacy against an inactive control (Williams et al. 2016).”
Is Poorly Assisted Psilocybin Treatment an Increasing Risk?
Schenberg, E. E., King, F., da Fonseca, J. E., & Roseman, L. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230664 · Cited by 32
Felsch, C. L., & Kuypers, K. P. C. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104724 · Cited by 29 · cited 1×
“…Eye Movement Desensitization and Reprocessing Therapy (EMDR; Rose and Raine-Smith 2023), existential psychology (Moreton et al. 2020), mindfulness (Felsch and Kuypers 2022), psychoanalysis (Guss 2022), group psycho-therapy (Trope et al. 2019), virtual reality therapy (Aday et al. 2020), and even…”
Psilocybin Without Psychotherapy: A Cart Without a Horse?
Earleywine, M., Leo, J. A. D., Bhayana, D., Rajanna, B., & Scott, K. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230572 · Cited by 28 · cited 1×
“…from researchers across the globe expressing concern that minimizing the psychotherapeutic component of treatment could compromise the safety and efficacy of PAP (Alpert et al. 2024; Bogenschutz 2024; Deckel et al. 2024; Earleywine et al. 2024; O’Donnell et al. 2024; Schenberg et al. 2024).”
Thal, S. B., Wieberneit, M., Sharbanee, J. M., Skeffington, P., Baker, P., Bruno, R., Wenge, T., & Bright, S. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221127954 · Cited by 26
Twomey, C. D., O’Reilly, G., & Goldfried, M. R. (2023) · Psychotherapy · doi:10.1037/pst0000489 · Cited by 26
Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary
Alpert, M. D., O’Donnell, K. C., Paleos, C. A., Sola, E., Stauffer, C. S., Wagner, A. C., Nicholas, C. R. N., & Mithoefer, M. C. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230665 · Cited by 22 · cited 1×
“…from researchers across the globe expressing concern that minimizing the psychotherapeutic component of treatment could compromise the safety and efficacy of PAP (Alpert et al. 2024; Bogenschutz 2024; Deckel et al. 2024; Earleywine et al. 2024; O’Donnell et al. 2024; Schenberg et al. 2024).”
Psychedelic-assisted therapy” must not be retired
Deckel, G. M., Lepow, L. A., & Guss, J. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230667 · Cited by 21 · cited 1×
“…from researchers across the globe expressing concern that minimizing the psychotherapeutic component of treatment could compromise the safety and efficacy of PAP (Alpert et al. 2024; Bogenschutz 2024; Deckel et al. 2024; Earleywine et al. 2024; O’Donnell et al. 2024; Schenberg et al. 2024).”
Zeifman, R. J., & Maia, L. O. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.09.007 · Cited by 18
A pragmatic approach to measuring adherence in treatment delivery in psychotherapy
Serfaty, M. A., Shafran, R., Vickerstaff, V., & Aspden, T. (2020) · Cognitive Behaviour Therapy · doi:10.1080/16506073.2020.1717594 · Cited by 17 · cited 1×
“(2020) published the Therapy Component Checklist (TCC) to measure adherence to manualized CBT.”
Wolfson, E. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00192 · Cited by 15 · cited 1×
“…(Moreton et al. 2020), mindfulness (Felsch and Kuypers 2022), psychoanalysis (Guss 2022), group psycho-therapy (Trope et al. 2019), virtual reality therapy (Aday et al. 2020), and even novel modalities specifically designed for PAP (Brennan and Belser 2022; Wolfson 2022; Watts and Luoma 2020).”
LYSERGIC ACID DIETHYLAMIDE IN PSYCHOTHERAPY. PART I: CLINICAL ASPECTS
Whitaker, L. H. (1964) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1964.tb133752.x · Cited by 13
Bogenschutz, M. P. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230643 · Cited by 13
International Journal of Social Sciences and Management Review
(2020) · International Journal of Social Sciences and Management Review · doi:10.37602/ijssmr · Cited by 11
Thal, S. B., Wieberneit, M., Sharbanee, J. M., Skeffington, P., Bruno, R., Wenge, T., & Bright, S. J. (2023) · Journal of Humanistic Psychology · doi:10.1177/00221678231168516 · Cited by 10
Thal, S. B., Engel, L. B., & Bright, S. J. (2022) · Addiction Research & Theory · doi:10.1080/16066359.2022.2065268 · Cited by 10 · cited 1×
“…the wide variety of terms used to describe individuals supporting patients through psychedelic experiences, such as “guide” (Leary 1966), “sitter” (Thal et al. 2022a) “monitor” (Ching et al. 2023), “facilitator” (Golden et al. 2022), and “psychedelic therapist” (Aday et al. 2023a), among others,…”
Kellett, S., Gausden, J., & Gaskell, C. (2021) · Psychology and Psychotherapy: Theory, Research and Practice · doi:10.1111/papt.12278 · Cited by 8
Ching, T. H. W., Grazioplene, R., Pittenger, C., & Kelmendi, B. (2023) · doi:10.31234/osf.io/ba42z · Cited by 6
Brennan, B., Kelman, A. R., & Belser, A. (2023) · doi:10.31234/osf.io/2ab59 · Cited by 4
Research works printed but not linked: 6
- Grob CS, Grigsby J (2021) Handbook of Medical Hallucinogens. The Guilford
- Grof S (1980) LSD Psychotherapy. Hunter House
- Leary T (1966) Psychedelic prayers after the Tao Te Ching, vol 1. Poets
- Luborsky L, Rosenthal R, Diguer L, Andrusyna TP, Berman JS, Levitt JT, Seligman DA, Krause ED (2002) The dodo bird verdict is alive and well–mostly. Clin Psychol Sci Pract 9:2–12
- Morgan NL (2020) Integrating psychedelic experiences utilizing the internal family systems therapeutic model. Int J Social Sci Manage Rev 3:257–264
- Rose J, Raine-Smith H (2023) EMDR as a preparation and integration tool in psychedelic-assisted therapy: a collaborative case study. EMDR Therapy Quarterly
Cited by
Wolff, M., Evens, R., Mertens, L. J., Schmidt, C., Beck, J. L., Rutrecht, H. M., Cherniak, A. D., Gründer, G., & Jungaberle, H. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241249698 · Cited by 42
“Agreeing with others who have pointed out that psychedelic therapy shares substantial “common factors” with other psycho-therapies (Aday et al., 2023; Greenway et al., 2020; Nayak and Johnson, 2020), we assume that therapeutically effective psy-chedelic experiences are similar to those experiences…”
BackgroundAddressing blinding in classic psychedelic studies with innovative active placebos
Aday, J. S., Simonsson, O., Schindler, E. A. D., & D’Souza, D. C. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf023 · Cited by 33
“…hype and parties with commercial interest 19 ), concomitant therapies that are proposed to work synergistically with classic psychedelics (eg, psychotherapy 8,56 ), curated settings that enhance the acute classic psychedelic experience, 57 and the role of the classic psychedelic experience itself.”
Self-citationKruger, D. J., Aday, J. S., Fields, C. W., Kolbman, N., Glynos, N. G., Barron, J., Herberholz, M., & Boehnke, K. F. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0011 · Cited by 28
“39 As the commercialization and medicalization of psy-chedelic treatments approach, 40 it will be crucial to characterize the range of potential adverse experiences one could be exposed to throughout the course of psychedelic treatment to identify and implement effective harm reduction strategies.”
Self-citationMenon, V., Ramamurthy, P., Venu, S., & Andrade, C. (2024) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13778 · Cited by 28
Aday, J. S., McAfee, J., Conroy, D. A., Hosanagar, A., Tarnal, V., Weston, C. L., Scott, K., Horowitz, D., Geller, J. A., Harte, S. E., et al. (2025) · Frontiers in Pain Research · doi:10.3389/fpain.2025.1527783 · Cited by 27
“As is standard in PAT research, the therapy component included preparatory, dosing, and integration sessions with the therapist dyad (42).”
Self-citation
Metadata
- Authors
- Aday, J. S., Horton, D., Fernandes-Osterhold, G., O’Donovan, A., Bradley, E. R., Rosen, R. C., & Woolley, J. D.
- Affiliations
- University of Michigan (US)
- University of Wisconsin–Madison (US)
- University of California, San Francisco (US)
- San Francisco VA Medical Center (US)
- Corresponding author
- Aday, Jacob S.
- Venue
- Psychopharmacology
- Published
- 2024-05-24
- Volume
- 241
- Issue
- 8
- Pages
- 1517-1526
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W4398774731
- Cited by
- 54
- References
- 87
- Citations by year
- 2026: 26 · 2025: 19 · 2024: 9
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- PsyArXiv (OSF Preprints) (submittedVersion, cc-by)
- Funders
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32AR007080)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psychedelic-assisted psychotherapy, psychotherapy models, psychological support, mechanisms of change, treatment standardization, substance use disorders, depression
- MeSH terms
- Mental Disorders, Hallucinogens, Humans, Psychotherapy, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.